Market Overview

UPDATE: CRT Capital Initiates Coverage on OncoGenex

Share:
Related OGXI
Here's Why Shares Of Onco Genex Pharma Are Plunging
OncoGenex Announces Update on Phase 2 Spruce Trial in Previously Untreated Metastatic Non-Small Cell Lung Cancer

CRT Capital Thursday morning ratings report included a coverage initiation by analyst Arlinda Lee on Oncogenex Pharmaceuticals (NASDAQ: OGXI) with a Buy rating and price target of $20.

The highlight for OGXI includes phase 3 trials of Curtisen and subsequent partnership with Teva, along with phase 2 trials of Apatorsen.

The report notes "The basis for our Buy rating is our optimism for a positive outcome from ongoing pivotal Phase 3 SYNERGY trial in castrate resistant prostate cancer (CRPC) in mid-2014. We expect FDA filing in 2H14 and approval in 20145. We also expect rapid uptake of custirsen to reach peak 35% penetration the US and 30% in EU."

OGXI closed the previous trading session at $11.51 and is currently trading around the $11.76 mark.

Latest Ratings for OGXI

DateFirmActionFromTo
Dec 2015Stifel NicolausDowngradesBuyHold
Sep 2015RBC CapitalMaintainsSector Perform
Apr 2014Stifel NicolausMaintainsBuy

View More Analyst Ratings for OGXI
View the Latest Analyst Ratings

Posted-In: CRT CapitalNews Price Target Initiation Markets Analyst Ratings

 

Related Articles (OGXI + TEVA)

View Comments and Join the Discussion!